Acepodia is a pioneering biotechnology company that is revolutionizing cancer treatment through the development of first-in-class, off-the-shelf allogeneic cell therapies. With a focus on hematologic and solid tumor cancers, Acepodia aims to provide highly effective and safe treatments that are accessible to a broad group of patients. Led by a team of accomplished professionals, including former executives from esteemed companies like Juno Therapeutics and Roche, Acepodia utilizes cutting-edge technologies to unlock the full potential of immune cell lines.

By harnessing the power of γδ2 T cells and NK cells and equipping them with proprietary platform technologies, such as Antibody-Cell Conjugation (ACC), Acepodia creates potent cancer-killing cells that can effectively target tumor cells. Acepodia's innovative approach offers powerful and accessible cell therapies for patients with cancer. Their commitment to developing groundbreaking treatments that are readily available to patients sets them apart in the field of cell therapy.

For more information, please visit Acepodia's website or contact them directly through email or phone